Expressions of surviving, MMP2, TIMP1, CD44 and nm23 of two tumors originating from different immunosurveillance in the same patient.
- Author:
Hui-ling LI
1
;
Zheng XIANG
;
Tong ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Female; Hematopoietic Stem Cell Transplantation; adverse effects; Humans; Hyaluronan Receptors; metabolism; Inhibitor of Apoptosis Proteins; metabolism; Lymphoma, Large B-Cell, Diffuse; etiology; metabolism; Matrix Metalloproteinase 2; metabolism; NM23 Nucleoside Diphosphate Kinases; metabolism; Neoplasms, Second Primary; metabolism; Precursor Cell Lymphoblastic Leukemia-Lymphoma; therapy; Tissue Inhibitor of Metalloproteinase-1; metabolism
- From: Journal of Southern Medical University 2010;30(6):1291-1294
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the differences in the survival, adhesion and diffusion capacity between different carcinomas originating from different immunosurveillance in the same patient.
METHODSThe expressions of survivin, MMP2, TIMP1, CD44, and nm23 proteins were detected immunohistochemically in a patient with acute lymphoblastic leukemia and lymphoma after allogeneic blood stem cell transplantation.
RESULTSSurvivin, MMP2, TIMP1, CD44, and nm23 proteins were positive in acute lymphoblastic leukemia samples obtained before transplantation and negative in the lymphoma tissue occurring after the transplantation.
CONCLUSIONThe expressions of survivin, MMP2, TIMP1, CD44, and nm23 proteins vary between the two carcinomas originating from different immunosurveillance in the same patient.
